" class="no-js "lang="en-US"> FDA Archives - Page 3 of 14 - Medtech Alert
Wednesday, October 01, 2025

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

The U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based […]

Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ for the Treatment of the Signs and Symptoms of Dry Eye Disease

Bausch + Lomb, a leading global eye health company dedicated to helping people see better […]

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

Prothena, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on […]

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Phio Pharmaceuticals, a clinical-stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to […]

Sarepta Therapeutics Announces Positive Vote from FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy

Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, today announced that the […]

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease

Otsuka Pharmaceutical and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the supplemental New […]

FDA Accepts Application for Roche’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

Roche has announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s […]

Brenus Pharma Unveils Groundbreaking Preclinical Results For STC-10101, a Promising New Drug Candidate Targeting Colorectal Cancer & Solid Tumors

Brenus Pharma announces two groundbreaking presentations on STC-1010, the company’s first drug candidate for colorectal […]

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease

Editas Medicine, a clinical stage genome editing company, today announced that the US Food and […]

Vertex Announces FDA Approval for TRIKAFTA in Children With Cystic Fibrosis

Vertex Pharmaceuticals has announced the U.S. Food and Drug Administration (FDA) approved the expanded use […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more